{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:06:07Z","timestamp":1767834367280,"version":"3.49.0"},"reference-count":12,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Vaccines"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> In May 2012, universal vaccination with the 13-valent pneumococcal conjugate vaccine (PCV-13) was introduced for all children in the Tijuana region of Mexico, with a coverage of 80%. <\/jats:p><\/jats:sec><jats:sec><jats:title>Method:<\/jats:title><jats:p> Between October 2005 and September 2013 active surveillance was undertaken for all invasive pneumococcal diseases (IPDs) in children admitted to the Tijuana General Hospital. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> Following PCV-13 implementation, there was a 75% reduction in overall IPD, and no cases of serotype 19A, pneumococcal meningitis, and pneumococcal-associated deaths. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p> These results are the first to show the effectiveness of PCV-13 in Mexico. <\/jats:p><\/jats:sec>","DOI":"10.1177\/2051013614547199","type":"journal-article","created":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T05:21:31Z","timestamp":1409635291000},"page":"155-158","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital"],"prefix":"10.1177","volume":"2","author":[{"given":"Enrigue","family":"Chacon-Cruz","sequence":"first","affiliation":[{"name":"Pediatric Infectious Diseases Service, Hospital General de Tijuana, Tijuana Baja-California, Paseo Centenario S\/N, Zona Rio, Tijuana, Baja-California, ZC 22010, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"Rivas-Landeros","sequence":"additional","affiliation":[{"name":"Microbiology Laboratory, Hospital General de Tijuana, Tijuana Baja-California, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Volker-Soberanes","sequence":"additional","affiliation":[{"name":"Microbiology Laboratory, Hospital General de Tijuana, Tijuana Baja-California, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,9,1]]},"reference":[{"key":"bibr1-2051013614547199","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2012.12.005"},{"key":"bibr2-2051013614547199","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000269"},{"key":"bibr3-2051013614547199","first-page":"893","volume":"54","author":"Centers for Disease Control and Prevention","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"bibr4-2051013614547199","volume-title":"Presented at the 29th Annual Meeting of the European Society for Paediatric Infectious Diseases","author":"Chacon-Cruz E.","year":"2011"},{"key":"bibr5-2051013614547199","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.1954"},{"key":"bibr6-2051013614547199","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318275614b"},{"key":"bibr7-2051013614547199","doi-asserted-by":"publisher","DOI":"10.1586\/erv.10.145"},{"key":"bibr8-2051013614547199","unstructured":"Pan American Health Organization (2014) SIREVA II. [http:\/\/www.paho.org\/hq\/index.php?option=com_content&view=category&layout=blog&id=3609&Itemid=3953]"},{"key":"bibr9-2051013614547199","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000294"},{"key":"bibr10-2051013614547199","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03938.x"},{"key":"bibr11-2051013614547199","doi-asserted-by":"publisher","DOI":"10.1586\/erv.10.163"},{"key":"bibr12-2051013614547199","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.03.017"}],"container-title":["Therapeutic Advances in Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2051013614547199","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2051013614547199","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2051013614547199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T13:26:23Z","timestamp":1740749183000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2051013614547199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,1]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1177\/2051013614547199"],"URL":"https:\/\/doi.org\/10.1177\/2051013614547199","relation":{},"ISSN":["2051-0144","2051-0136"],"issn-type":[{"value":"2051-0144","type":"print"},{"value":"2051-0136","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,1]]}}}